Protagonist Therapeutics (PTGX) shares experienced a significant rally, climbing nearly 7% over the past week following a major regulatory breakthrough. The surge comes after Johnson & Johnson (JNJ) received approval from the U.S. Food and Drug Administration (FDA) for Icotyde (JNJ-2113). This medication is specifically designed for the treatment of moderate-to-severe plaque psoriasis in adult patients. For Protagonist, this regulatory milestone serves as a critical financial catalyst, triggering substantial milestone payments from its partner. Furthermore, the approval establishes a long-term revenue stream through potential royalties on future sales of the drug. Market analysts view this development as a validation of Protagonist’s drug development platform and its strategic partnership with JNJ.
Sign up free to access this content
Create Free Account